A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.
Opinion|Podcasts|April 5, 2024
Dyskinesia: Importance of Giving Patients More Good “On- Time" in Parkinson’s Disease
Listen
0:00 / 0:00
Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.
Advertisement
1:30 Defining ON time in PD
4:50 Dyskinesia experience
8:15 Tremor and dyskinesia
13:40 Dyskinesia and QoL
16:10 Dyskinesia and OFF
18:35 Tailoring treatment
23:25 Amantadine DR/ER
28:50 Amantadine candidates
Advertisement
Related to this article
The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.
Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and nonmotor symptoms in Parkinson disease.
New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.
An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.
Phase 2a trial results showed 800 mg vutiglabridin significantly improved motor symptom scores compared with placebo in early-stage Parkinson's disease.
Investigational oral dopamine agonist prodrug boosts good ON-time, cuts OFF-time and dyskinesia, and reduces levodopa in advanced Parkinson disease, as phase 2 begins.
The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of African ancestry.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
MDS Congress 2026: Late-Breaking Data Snapshot
2
The Road Ahead for Precision Medicine in Multiple Sclerosis
3
Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis
4
New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy
5